Schonfeld Strategic Advisors’s Spyre Therapeutics SYRE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69M	Buy	+19,089	New	+$1.39M	0.01%	1161
2025 Q4	–	Sell	-81,474	Closed	-$1.37M	–	2568
2025 Q3	$1.37M	Buy	+81,474	New	+$1.33M	0.01%	1228
2024 Q4	–	Sell	-46,072	Closed	-$1.35M	–	2368
2024 Q3	$1.35M	Sell	46,072 -32,428	-41%	-$903K	0.01%	1046
2024 Q2	$1.85M	Buy	78,500 +43,000	+121%	+$1.45M	0.01%	940
2024 Q1	$1.35M	Buy	+35,500	New	+$1.03M	0.01%	1118
2022 Q3	–	Sell	-404	Closed	-$5K	–	3154
2022 Q2	$5K	Buy	+404	New	+$14.2K	﹤0.01%	2324

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Schonfeld Strategic Advisors's SYRE Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 19,089 shares worth $1.69M. The stake represents 0.01% of the portfolio and ranks #1161 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in SYRE as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in SYRE in Q2 2022 and has held it in 6 quarters since. The position peaked at $1.85M in Q2 2024. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Schonfeld Strategic Advisors held 19,089 shares of Spyre Therapeutics worth $1.69M as of Q2 2026.
Spyre Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
Spyre Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1161 holding.
Schonfeld Strategic Advisors first reported a position in Spyre Therapeutics in Q2 2022 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's Spyre Therapeutics position peaked at $1.85M in Q2 2024.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.